Insiders Trades
Cryoport, Inc.: what insiders have been doing
Cryoport, Inc. belongs to the Industry sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 26 filings signed by 12 insiders.
The flow runs one way only: 10 sales worth €2.9M, from 5 insiders, and no purchase. No amount is published for 3 filings, which the totals therefore leave out. One trade stands out by size: a sale of €2.4M from Stefanovich Robert, disclosed on 8 June 2026, or 0.30% of market capitalisation.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 26 filings here. The full history, which starts in 2016, counts no purchases against 38 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 176.2 m USD and net income at 78.3 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Tennant Co and Butler National Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
156
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€87M
38 ops. · all time
Who traded when
BuySaleJerrell Shelton4 sales
Ramkumar Mandalam3 sales
Robert J. Hariri3 sales
Robert Stefanovich3 sales
Edward J. Zecchini2 sales
Mark W. Sawicki2 sales
Analyst consensus: bullish or bearish?
Analysts rate Cryoport, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$19.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,623 of 24,148 companies
58.7
score / 100
Value56
Quality62
FCF yld-3.3%
Earn yld9.3%
EV/EBITDA·
ROE-6.5%
Gross mgn47%
Net mgn44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.64
Analyst consensus
9 analystsStrong buy
US$15.00Target US$19.78(+19%)US$26.00
Income statement
RevenueUS$176.2M
Gross profitUS$83.1M47% margin
EBITDA-US$2.1M-1% margin
Net incomeUS$78.3M-20.1% margin
Valuation
PER (forward)-25.1x
P/Book1.9x
Beta1.96
Balance sheet & cash
Market capUS$842.8M
Total debtUS$230.7M
Free Cash Flow-US$28.1M
Debt / Equity47%
Profitability & ownership
ROE-6.5%
ROA-2.4%
% insiders3.9%
% institutions95.2%
Last declaration on 11 August 2026
Declarations156 total
28,800 shares@ US$14.820.048% mcap100.0% of flowCommonSEC144:0001950047-26-007965
28,800 shares@ US$14.90920.048% mcap12.9% of flowCommon StockSEC:0001104659-26-094228:0
1,400 sharesCommon StockSEC:0001104659-26-073630:0
1,400 sharesCommon StockSEC:0001104659-26-073630:1
33,600 sharesCommon StockSEC:0001104659-26-073630:2
33,600 sharesCommon StockSEC:0001104659-26-073630:3
33,600 shares@ US$14.47140.059% mcap95.8% of flowCommonSEC144:0001950047-26-005914
1,400 shares@ US$15.23140.0027% mcap4.2% of flowCommonSEC144:0001950047-26-005868
10,350 shares0Common StockSEC:0001104659-26-071724:0
23,214 shares@ US$15.44120.045% mcap100.0% of flowCommonSEC144:0001950047-26-005741
23,214 sharesCommon StockSEC:0001104659-26-071506:1
169,427 shares@ US$16.27240.30% mcap78.5% of flowCommon StockSEC:0001104659-26-071509:0
10,350 shares0Common StockSEC:0001104659-26-071506:0
10,350 shares0Common StockSEC:0001104659-26-071507:0
10,350 shares0Common StockSEC:0001104659-26-071508:0
169,427 shares@ US$16.500.35% mcap80.0% of flowCommonSEC144:0001973097-26-000017
104,007 shares@ US$1.870.024% mcap16.0% of flowCommon StockSEC:0001104659-26-047945:0
50,000 shares@ US$1.877.8% of flowCommon StockSEC:0001104659-26-041041:0
1,094 shares@ US$8.180.3% of flowCommon StockSEC:0001104659-26-034754:0
2,894 shares@ US$8.182.0% of flowCommon StockSEC:0001104659-26-034753:0
1,341 shares@ US$8.181.8% of flowCommon StockSEC:0001104659-26-034752:0
7,918 shares@ US$8.001.9% of flowCommon StockSEC:0001104659-26-029719:0
22,845 shares0Common StockSEC:0001104659-26-029718:0
21,322 shares0Common StockSEC:0001104659-26-029720:0
87,188 shares@ US$1.874.7% of flowCommon StockSEC:0001104659-26-028775:0
25 of 156 declarations
About Cryoport, Inc.
Cryoport, Inc. (NASDAQ: CYRX) is a specialized life sciences supply-chain company headquartered in Brentwood, Tennessee, United States. Founded in 1999, it has evolved from a logistics-focused business into an integrated platform serving biopharmaceutical, animal health, and human reproductive medicine markets. For investors, Cryoport should be viewed less as a traditional transporter and more as mission-critical infrastructure for temperature-sensitive and high-value biological products.
The company’s core business centers on temperature-controlled logistics, cryogenic and ultra-cold shipping systems, bio-storage, and related services for advanced therapies. Its platform supports cell and gene therapy developers, biologics manufacturers, clinical trial programs, and other sensitive life-science applications. Over time, Cryoport has broadened its offering beyond shipping into cryopreservation, biostorage, packaging, labeling, kit production, and logistics orchestration. That broader scope increases wallet share and makes the company more embedded in customer workflows.
Read moreShow less
Cryoport’s competitive positioning is built on specialization, compliance, and operational reliability. In advanced therapies, where product integrity and chain-of-custody are essential, the company’s expertise in regulated, temperature-controlled supply chains creates meaningful barriers to entry. Its value proposition is tied to reducing risk for customers running complex global programs, especially in cell and gene therapy, where a logistics failure can destroy a high-value batch. The group emphasizes its global reach across the Americas, EMEA, and APAC, with more than 50 strategic locations and a customer base exceeding 3,000 worldwide.
Recent developments underline the company’s strategic expansion. In June 2024, Cryoport officially launched its Global Supply Chain Hub in Stevenage, U.K., strengthening its European footprint. In January 2025, it announced a strategic partnership with Moffitt Cancer Center to establish a state-of-the-art biorepository center in Florida. Its 2024 annual report also showed continued traction in its core market, with 701 clinical trials supported globally at year-end 2024, including 81 phase 3 trials. More broadly, Cryoport remains a growth-oriented platform leveraged to the expansion of advanced therapies, but its investment case depends on execution, commercial adoption in cell and gene therapy, and the company’s ability to translate its international footprint into durable profitability.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
